Trial
NCT01349192
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
University of North Carolina, Chapel Hill
Collaborators
CF Therapeutics Development Network Coordinating Center; Seattle Children's Hospital; Washington University School of Medicine; University of Washington; University of Colorado, Denver; Baylor College of Medicine; University of Alabama at Birmingham; Cook Children's Medical Center; University of Michigan; University of Florida; University of Texas Southwestern Medical Center; Children's Hospital Medical Center, Cincinnati; St. Louis Children's Hospital
Condition
Cystic Fibrosis
Intervention
Rifampin
Why stopped
Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-15